2-guanylbenzimidazole | 69006-93-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-guanylbenzimidazole
• 英文别名: 1H-benzoimidazole-2-carboximidic acid amide；1H-Benzimidazole-2-carboximidamide
• CAS: 69006-93-5
• 化学式: C₈H₈N₄
• mdl: MFCD00022678
• 分子量: 160.178
• InChiKey: DKMZVRTWQBZKME-UHFFFAOYSA-N

物化性质

• 沸点：
  377.5±25.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.6
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1H-苯并咪唑-2-甲腈 、 氨 以53%的产率得到
  参考文献：
  名称：

  BUKOWSKI L., ACTA POL. PHARM., 1978, 35, NO 3, 295-299,

  摘要：

  DOI：

文献信息

• NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES
  申请人：Naftchi Eric N.

  公开号：US20070082918A1

  公开（公告）日：2007-04-12

  Pharmacologically active compounds suitable for treating a mammal so as to affect neurological function, the compounds comprising at least two neurologically active groups, one group providing alpha-adrenergic agonist activity, and the second group providing agonist activity selected from the group consisting of beta-adrenergic agonist activity, serotinergic agonist activity, dopaminergic agonist activity, and GABA-ergic agonist activity. Each of the compounds being lipophilic, capable of crossing the blood/central nervous system barrier and effective as the primary therapeutic agent, in a dosage amount and at a dosage rate sufficient to provide the desired effect. Therapeutic compositions comprising the compound are provided.

  具有药理活性的化合物，适用于治疗哺乳动物以影响神经功能，该化合物包括至少两个神经活性基团，其中一个基团提供α-肾上腺素能激动剂活性，第二个基团提供从以下组中选择的激动剂活性：β-肾上腺素能激动剂活性、血清素能激动剂活性、多巴胺能激动剂活性和GABA-能激动剂活性。每种化合物都是亲脂性的，能够穿过血液/中枢神经系统屏障，并且在剂量和剂量速率足以提供所需效果的情况下作为主要治疗剂有效。提供了包含该化合物的治疗组合物。
• CURING AGENTS FOR COMPOUNDS
  申请人：E. I. du Pont de Nemours and Company

  公开号：EP3239227A2

  公开（公告）日：2017-11-01

  Curing fluoroelastomers using curing agents of formula, R1N=CR2R3, wherein R1 is H; R2 is selected from the group consisting of H, NH2, and NR4R5; R3 is selected from the group consisting of Ph, SO2H, NR6R7,2-pyridine, and CH2CONH2; R4 is H; R5 is selected from the group consisting of Ph, NH2, and CN; R6 is selected from the group consisting of H, NHPh, CCONH2, C1 to C8 linear alkyl group, and C1 to C8 branched alkyl group; and R7 is selected from the group consisting of Ph, COOC(CH3)3, NH2, CH2COOH, CSNH2, CNHNH3+ Cl-, p-phenylCN, COPh,

  使用式 R1N=CR2R3 的固化剂固化氟橡胶，其中 R1 为 H；R2 选自由 H、NH2 和 NR4R5 组成的组；R3 选自由 Ph、SO2H、NR6R7、2-吡啶和 CH2CONH2 组成的组；R4 为 H；R5 选自由 Ph、NH2 和 CN 组成的组；R6 选自由 H、NHPh、CCONH2、C1 至 C8 直链烷基和 C1 至 C8 支链烷基组成的组；以及 R7 选自由 Ph、COOC(CH3)3、NH2、CH2COOH、CSNH2、CNHNH3+ Cl-、对苯基 CN、COPh 组成的组、
• Curing agents for compounds
  申请人：DuPont Polymers, Inc.

  公开号：US10472494B2

  公开（公告）日：2019-11-12

  Curing fluoroelastomers using curing agents of formula, R1N═CR2R3, wherein R1 is H; R2 is selected from the group consisting of H, NH2, and NR4R5; R3 is selected from the group consisting of Ph, SO2H, NR6R7, 2-pyridine, and CH2CONH2; R4 is H; R5 is selected from the group consisting of Ph, NH2, and CN; R6 is selected from the group consisting of H, NHPh, CCONH2, C1 to C8 linear alkyl group, and C1 to C8 branched alkyl group; and R7 is selected from the group consisting of Ph, COOC(CH3)3, NH2, CH2COOH, CSNH2, CNHNH3+Cl−, p-phenylCN, COPh,

  使用式 R1N═CR2R3 的固化剂固化氟橡胶，其中 R1 为 H；R2 选自由 H、NH2 和 NR4R5 组成的组；R3 选自由 Ph、SO2H、NR6R7、2-吡啶和 CH2CONH2 组成的组；R4 为 H；R5 选自由 Ph、NH2 和 CN 组成的组；R6 选自由 H、NHPh、CCONH2、C1 至 C8 直链烷基和 C1 至 C8 支链烷基组成的组；以及 R7 选自由 Ph、COOC(CH3)3、NH2、CH2COOH、CSNH2、CNHNH3+Cl-、对苯基 CN、COPh 组成的组、
• ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP0874629B1

  公开（公告）日：2004-05-19
• M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP0892780B1

  公开（公告）日：2002-11-20